About us

Our customers have always known that they can depend on MSD Animal Health for more than just medicines. They count on MSD Animal Health for information, technologies and veterinary services that truly advance animal healthcare. It is our heritage and our mission.

The Science of Healthier Animals

Today, our science supports the precious bond between people and their pets. It also helps protect international public health, ensure food safety and increase protein supplies.

Our core values

Today, our science supports the precious bond between people and their pets. It also helps protect international public health, ensure food safety and increase protein supplies.

RESPONSIBLE

Appreciating the fundamental role of progressive science in animal health, understanding the deep responsibility MSD Animal Health has to our customers, consumers, animals, society and the planet.

VISIONARY

Being original in thought and approach, having the confidence and determination to come up and work with new insights, greater understanding and fresh knowledge.

COLLABORATIVE

Working closely, sharing understanding and inspiring one another and customers, allowing science and thinking to flourish, enabling the right balance of cost against human capability.

DYNAMIC

Aiming at being efficient, fast and flexible in all operations, responding rapidly to new opportunities and demands, an outward orientated performance culture that values talent and action.

Our People

Bringing our purpose to life.

“My professional growth has been exponential … so currently I lead a team of professionals and key account managers, sales people, technical people, and collectively, we have 375 years of experience with the company.”

João, swine & poultry business unit, Animal Health Spain 

“My job is to keep things running… I know I’m successful when nothing goes wrong.”

— Cliff, service management specialist, Animal Health IT 

“We all share the same passion, which is the love for animals and wanting to improve their lives.”

Daniel, director, Digital Center of Excellence 

“No matter your background, you’re part of this team and part of the future success.”

— Ellen, senior marketing specialist, Pet Technology Support 

“I’ve really had the opportunity to explore all and any of my professional passions.”

Elise, director, companion animal business unit, Animal Health France 

I Am Animal Health is a series of stories about our people

A Legacy of Innovation

MSD Animal Health has a rich heritage of scientific excellence and innovation. It is the foundation of our future and the inspiration for our daily work.

2024

  • MSD Animal Health receives approval from the European Commission for BRAVECTO® for injection for dogs for the immediate and persistent killing of fleas and ticks.

  • MSD Animal Health receives CVMP positive opinion for NOBILIS MULTRIVA™ RT+IBm+ND+Gm+REOm+EDS poultry vaccine, which protects against diseases caused by avian metapneumovirus also known as Turkey Rhinotracheitis (RT) virus, Infectious Bronchitis (IB) virus, Newcastle disease (ND) virus, Infectious Bursal disease or Gumboro (G) virus, Reovirus (REO) and Egg Drop Syndrome (EDS) virus.

  • MSD Animal Health introduces the BIOMARK® IS1001 MUX multiplexing transceiver, which connects up to six separate antennas to deliver superior performance for the assessment of fish movement and passage in riverine environments.

  • MSD Animal Health receives license approval from the U.S. Department of Agriculture for INNOVAX®-ILT-IBD vaccine for combined protection and immunization against Marek’s disease (MD), Infectious Laryngotracheitis (ILT) and Infectious Bursal Disease (IBD) in a single injection

  • MSD Animal Health introduces a redesigned ALLFLEX® A-Tag™ Feedlot V2 and applicator as part of its comprehensive feedlot portfolio for easier application, faster loading and improved retention, providing feedyard and stocker cattle operators with a new option for visual identification.

  • MSD Animal Health receives approval from the European Commission for PORCILIS® PCV M Hyo ID, a ready-to-use intradermal vaccine that offers protection against two of the most common swine pathogens: Porcine Circovirus Type 2 (PCV2) and Mycoplasma hyopneumoniae (M. hyo).   

  • MSD Animal Health introduces expansion of the NOBIVAC® NXT vaccine platform to protect cats against one of the most common feline infectious diseases, feline leukemia virus (FeLV). 

  • MSD Animal Health launches SenseHub™ Dairy Youngstock for pre-weaned calves in individual hutches and group housing, which is the industry’s first monitoring technology for dairy calves from birth through the first 12 months of life. The technology helps dairy workers quickly locate animals that need attention and use labor more efficiently.

  • MSD Animal Health completes its acquisition of the aqua business of Elanco Animal Health Incorporated, which bolsters the company’s position in the aqua industry with a comprehensive approach to promote fish health, welfare and sustainability in aquaculture, conservation and fisheries.

  • MSD Animal Health receives license approval from the U.S. Department of Agriculture for NOBIVAC® NXT Canine Flu H3N2, a next-level solution to help safeguard dogs against the ongoing threat of canine influenza. 

  • MSD Animal Health announces the launch and availability of the NOBIVAC® NXT Rabies portfolio, consisting of NOBIVAC® NXT Feline-3 Rabies and NOBIVAC® NXT Canine-3 Rabies – in Canada.

  • MSD Animal Health receives approval from the European Commission for INNOVAX®-ND-H5 Vaccine for use in chickens, which is the first centrally registered vaccine in the EU against the currently circulating avian influenza virus strains of clade 2.3.4.4b, which cause high mortality in poultry.

  • MSD Animal Health receives approval from the European Medicines Agency for an expanded indication for BOVILIS® ROTAVEC® CORONA for the subcutaneous injection of pregnant cows and heifers to raise antibodies against E. coli adhesins F5 (K99) and F41, rotavirus and coronavirus.

2023

  • MSD Animal Health receives the Best New Food Animal Product from S&P Global Animal Health for CIRCUMVENT® CML. It is the first and only ready-to-use, single-dose intramuscular injectable vaccine against disease caused by Porcine Circovirus Types 2a and 2d, Mycoplasma hyopneumoniae and Lawsonia intracellularis in pigs, three weeks of age and older.

  • MSD Animal Health receives approval from the European Commission for BOVILIS CRYPTIUM®, the first EU-licensed vaccine to protect cattle against Cryptosporidium parvum (C. parvum) infection, which is a highly infectious zoonotic parasite that causes cryptosporidiosis, one of the most significant gastrointestinal diseases in cattle.

  • MSD Animal Health receives approval from the Australian Pesticides and Veterinary Medicines Authority and the Peruvian Ministry of Health of an injectable formulation of BRAVECTO®, the first and only injectable parasiticide to provide up to a full year of flea and tick protection for dogs.

  • MSD Animal Health receives Best New Food Animal Product recognition from S&P Global Animal Health for SENSEHUB® Feedlot, a technology that provides real-time data to detect potentially sick cattle earlier, more efficiently and accurately than traditional visual observation.

  • MSD Animal Health receives U.S. Food and Drug Administration approval of an expanded indication for BANAMINE TRANSDERMAL® for the control of fever due to mastitis in dairy cattle.

  • MSD Animal Health announces availability of the canine oncology therapy, gilvetmab, to board-certified veterinary oncologists in the U.S. for treatment of dogs with mast cell tumors or melanomas.

  • MSD Animal Health receives U.S. Food and Drug Administration approval of an expanded indication for BRAVECTO® Chews for Dogs. The new indication treats and controls Asian longhorned ticks, which are an invasive Ixodid species located across more than one-third of the U.S.

  • MSD Animal Health launches CIRCUMVENT® CML, the first ready-to-use, single-dose vaccine effective against disease caused by Porcine Circovirus Types 2a and 2d, Mycoplasma hyopneumoniae and Lawsonia intracellularis in pigs, three weeks of age or older. 

  • MSD Animal Health launches FALCON® Biomass, a powerful, always-on biomass estimation unit that provides key information about average weight, distribution and growth trends to improve fish farming operations.

  • MSD Animal Health receives approval from the European Commission for INNOVAX®-ILT-IBD, a dual-construct HVT vaccine that provides long-term protection against infectious laryngotracheitis (ILT), infectious bursal disease (IBD) and Marek’s disease (MD). 

  • MSD Animal Health receives CVMP positive opinion for BOVILIS CRYPTIUM®, a vaccine to protect cattle against Cryptosporidium parvum (C. parvum) infection, in the European Union. C. parvum is a highly infectious zoonotic parasite that causes cryptosporidiosis, one of the most significant gastrointestinal diseases in cattle.

  • MSD Animal Health announces availability of the SEQUIVITY® IAV-S NA (Swine Influenza Vaccine, N1 and N2, RNA Particle) vaccine. The vaccine is the first commercial vaccine that uses only the influenza neuraminidase (NA) surface antigen to vaccinate pigs against influenza strains H1N1, H1N2 and H3N2. The company received license approval for the vaccine from the U.S. Department of Agriculture in 2022.  

2022

  • MSD Animal Health announces findings of its third veterinarian wellbeing study in collaboration with the American Veterinary Medical Association (AVMA), including a $100,000 grant to address wellbeing and mental health development among veterinarians, technicians and staff.

  • MSD Animal Health announces SENSEHUB Feedlot, state-of-the-art technology that features an illuminating electronic ear tag that makes it easy for animal care handlers to identify and sort beef cattle needing attention with less labor and minimal disruption to other animals.

  • MSD Animal Health receives approval from the European Commission of an additional indication for the vaccine, BOVILIS® INtranasal RSP® Live, to be used for the active immunization of young calves to reduce clinical signs of respiratory disease and viral shedding from infection with BRSV and PI3, two respiratory pathogens. 

  • MSD Animal Health receives U.S. Food and Drug Administration approval for  NUFLOR®‑S (florfenicol) Injectable Solution indicated for treatment of Swine Respiratory Disease.

  • MSD Animal Health launches its line of Hyper InfusiO2n solutions designed to improve fish attraction and passage at dam facilities by efficiently supplying stable, dissolved oxygen throughout fish passageways.

  • MSD Animal Health launches the DNA TRACEBACK® Fisheries Platform, a new DNA-based analytical tool which helps governments and fishery agencies to identify the sustainable yield of wild fish stocks and our customers to more accurately identify the total allowable catch for fishermen in their region.

  • MSD Animal Health receives license approval  from the U.S. Department of Agriculture for the Circumvent® CML vaccine for swine.   

  • MSD Animal Health acquires Vence, an innovator in virtual fencing solutions for rotational grazing and livestock management.

  • MSD Animal Health announces a minority investment in LeeO Precision Farming B.V., which provides a digital swine traceability solution for farmers, producers and retailers to track and analyze swine from birth throughout their lifecycle, including distribution of LeeO’s solution in selected markets.

  • MSD Animal Health opens a manufacturing facility for its animal intelligence products in Baton Rouge, Louisiana, broadening its manufacturing capacity and capabilities for its identification ear tags.

  • MSD Animal Health launches the Allflex DataFlow™ II System mobile app as part of its livestock intelligence portfolio.

  • MSD Animal Health reintroduces its CORVAC-3® vaccine in the U.S. to help poultry producers combat recent outbreaks of avian coryza.

2021

  • MSD Animal Health announces WHISPER® ON ARRIVAL, a first-of-its-kind precision tool that uses a multitude of factors to predict which cattle may be at higher risk of sickness.

  • MSD Animal Health expands its SEQUIVITY® veterinary prescription vaccine platform for sapovirus, an emerging virus causing diarrhea in young pigs.

  • MSD Animal Health launches FELAQUA® CONNECT, a water delivery and drinking monitoring system. Cat owners can track daily water intake via the SURE PETCARE™ App, while the smart water delivery system provides cats with fresh water.     

  • MSD Animal Health announces EXZOLT® as the first veterinary product centrally registered in the European Union to include animal welfare improvement in its Summary of Product Characteristics following a CVMP positive opinion in the European Union.  

  • MSD Animal Health receives approval from the European Commission of NOBIVAC® DP PLUS, a vaccine that provides protection against canine parvovirus (CPV) and canine distemper virus (CDV) during the most vulnerable stage of a puppy’s life.

  • MSD Animal Health receives approval from the European Commission of NOBIVAC® Respira Bb, an injectable vaccine to reduce clinical respiratory signs and shedding of infection caused by Bordetella bronchiseptica, one of the most widely recognized causes of canine cough.

  • MSD Animal Health launches a One Health approach to collaboratively improve health for the people and animals that share our complex and ever-changing environment.

  • MSD Animal Health was named best animal health company in North America by IHS Markit, the most widely read publication reporting on the animal health industry. The company also won the best new food animal product for WHISPER® ON ARRIVAL, the first-of-its-kind precision tool that predicts which cattle will benefit from treatment for the control of Bovine Respiratory Disease (BRD), one of the most prevalent diseases in beef cattle.

  • MSD Animal Health launches the Allflex UTT3S ear tag applicator, bringing simplicity and ergonomics to ear tag application while maximizing animal comfort and safety.   

  • MSD Animal Health launches the Allflex Flex V2 tag, featuring the first-of-its-kind multi-function LED indicator, to allow dairy producers and veterinarians to identify cows that need attention based on Allflex monitoring data.  

2020

  • MSD Animal Health receives CVMP positive opinion for INNOVAX®-ND-ILT in the European Union for protection against Marek’s Disease, Infectious Laryngotracheitis and Newcastle Disease

  • MSD Animal Health receives approval from the European Commission of  NOBILIS® SALENVAC® ETC, an inactivated trivalent Salmonella vaccine for poultry.

  • MSD Animal Health introduces the INNOJECT Pro, a subcutaneous chick vaccination technology for increased accuracy of injection and greater sustainability during the vaccination process, reducing stress to chicks.

  • MSD Animal Health receives a conditional license approval for gilvetmab, a caninized monoclonal antibody for treatment of dogs with mast cell tumors or melanomas, from the U.S. Department of Agriculture Center for Veterinary Biologics.

  • MSD Animal Health forms specialized operating unit, called MSD Animal Health Intelligence, to focus on animal health intelligence and data expertise.

  • MSD Animal Health acquires Quantified Ag, a data and analytics company that monitors cattle body temperature and movement in order to detect illness early.

  • MSD Animal Health acquires IdentiGEN, a leader in DNA-based  animal traceability solutions for Livestock and Aquaculture to accurately and precisely trace meat and poultry that is verifiable from fork-to-farm.

  • MSD Animal Health acquires U.S. rights to the SENTINEL® brand of combination parasiticides for Companion Animal, offering internal and external parasite protection.

  • MSD Animal Health receives U.S. Food and Drug Administration approval for  BRAVECTO® monthly chews for dogs and puppies 8 weeks of age and older for treatment and prevention of fleas and treatment and control of ticks.

  • MSD Animal Health receives U.S. Department of Agriculture approval for NASALGEN® 3, a three-way intranasal vaccine that protects beef and dairy cattle from the most common pneumonia-causing viral pathogens.

  • MSD Animal Health receives U.S. Food and Drug Administration approval for SHUTOUT™, an easy-to-administer teat sealant for the prevention of new intramammary infections throughout the dry period – the timeframe when cows are at the greatest risk.

  • MSD Animal Health announces results of a comprehensive study of wellbeing and mental health among U.S. veterinarians, which are critical issues facing the veterinary profession.

  • MSD Animal Health receives U.S. Food and Drug Administration approval for PORCILIS® Ileitis for multi-dose administration to vaccinate against ileitis caused by Lawsonia intracellularis.

  • MSD Animal Health announces $100 investment in facility expansion and enhancement efforts in its DeSoto, Kansas, manufacturing operations, including technological expansion of a vaccine production facility.

  • MSD Animal Health acquires worldwide rights to VECOXAN® brand of parasiticides to prevent coccidiosis for the Ruminant portfolio, available in Europe, South Africa, South Korea and Japan.

2019

  • MSD Animal Health receives approval from the European Commission of  PORCILIS® Lawsonia intramuscular vaccine for piglets.

  • MSD Animal Health collaborates with Rapid Genomics for exclusive rights to a  vaccination verification tool, Viral Flex-Seq®, for use in combination with INNOVAX® vaccines, to optimize and enhance disease outbreak management in poultry.

  • MSD Animal Health acquires Allflex Livestock Intelligence, Sure Petcare and Biomark, as leaders in animal health digital tracking, traceability and monitoring technology for Livestock and Companion Animal.

  • MSD Animal Health acquires Vaki, a leader in fish farming and wild fish conservation monitoring equipment and real-time video monitoring technology to advance fish health and welfare.

  • MSD Animal Health acquires Scan Aqua AS, a fish health and fish welfare company in Norway.

  • MSD Animal Health signs a Memorandum of Understanding with Nanolek for establishment of a local vaccine manufacturing facility in Russia.

  • MSD Animal Health receives U.S. Food and Drug Administration approval for BRAVECTO® PLUS topical solution for cats, providing extended-duration, broad-spectrum coverage of internal and external parasites.

2018

  • MSD Animal Health receives CVMP positive opinion for BRAVECTO® Plus spot-on solution for cats in the European Union for nose-to-toe parasite protection.

  • MSD Animal Health receives approval from the European Commission of an expanded indication of PANACUR® AquaSol to combat three gastrointestinal parasites in chickens. PANACUR AquaSol was originally approved in 2012 for the same indication in pigs to treat three similar types of parasites.

    • MSD Animal Health introduces the IDAL® 3G needle-free, intradermal swine vaccination device within their IDAL® way extended vaccine portfolio.

    • MSD Animal Health partners with Vinovo B.V. on novel delivery system to protect against highly infectious poultry diseases.

    • MSD Animal Health acquires animal vaccine company in China, including a manufacturing and R&D facility for expanded vaccine production.

      • MSD Animal Health introduces INNOVAX®-ND-IBD, the first live vaccine in the United States, made with biotechnology that protects against three highly infectious diseases in poultry – Newcastle Disease (ND), Infectious Bursal Disease (IBD) and Marek’s Disease (MD).

      • MSD Animal Health introduces its SEQUIVITY™ Technology, a highly innovative and highly advanced RNA Particle Technology used to create flexible, safe and precise vaccine solutions to new and evolving disease challenges.

      • MSD Animal Health announces the results of a large, well-controlled study with veterinarians designed to definitively quantify the prevalence of mental illness and stress in the veterinary profession and compare the findings to previous studies and the general U.S. population.

      2017

      • MSD Animal Health acquires Prondil S.A., a privately held company in Uruguay specializing in development and manufacturing of animal health vaccines for livestock.

      • MSD Animal Health acquires Vilsan Pharmaceuticals, a privately held producer of animal health products in Turkey, notably for ruminants.

      • MSD Animal Health acquires Vallée, a privately held producer of animal health products in Brazil.

      • MSD Animal Health announces its Whisper Veterinary Stethoscope System, a tool specifically designed to evaluate lung disease severity for more accurate diagnosis of Bovine Respiratory Disease (BRD).

      2016

      • MSD Animal Health receives U.S. Food and Drug Administration approval and CVMP positive opinion for BRAVECTO® for both cats and dogs in the European Union, up to 12 weeks of treatment and prevention of fleas and ticks.

      • The company becomes the first company to receive U.S. Department of Agriculture approval for NOBIVAC® Canine Influenza H3N2 Vaccine (CIV) to protect dogs against the newly identified strain of CIV.

      2015

      • MSD Animal Health receives a conditional product license from U.S. Department of Agriculture for NOBIVAC® Canine Influenza H3N2 Vaccine (CIV).

      • MSD Animal Health acquires Harrisvaccines, a privately held company that develops, manufactures and sells vaccines for food production and companion animal.

      2014

      • MSD Animal Health receives U.S. Food and Drug Administration approval of BRAVECTO®, the first chewable tablet for dogs for up to 12 weeks of treatment and prevention of fleas and ticks.

      • MSD Animal Health receives approval of PORCILIS® PCV M Hyo vaccine, Europe’s first single-shot vaccine to protect piglets from Porcine Circovirus Type 2 and Mycoplasma hyopneumoniae infections.

      2011

      • The operating name of the animal health unit changes to MSD Animal Health.

      2009

      • Development of SPHEREON® freeze-drying technology for vaccines (Intervet/Schering-Plough Animal Health).

      • MSD acquires Schering-Plough. Intervet/Schering-Plough Animal Health becomes the animal health division of MSD, including HomeAgain®, a leader in microchip and pet recovery services.

      2007

      • Schering-Plough acquires Organon Biosciences (Intervet and Organon) from AKZO NOBEL. The animal health division operates as Intervet/Schering-Plough Animal Health.

      2005

      • Harrisvaccines was founded in Iowa (United States).

      2000s

      • Launch of SLICE® fish antiparasitic for the treatment of sea lice in salmon (Schering-Plough Animal Health).

      • Licensure of the first live bacterial recombinant vaccine against strangles in horses in the EU (Intervet).

      • Introduction of PORCILIS® Pesti, the first marker vaccine for classical swine fever (Intervet).

      1997

      • MSD and French pharmaceutical company Rhone-Merieux (later Sanofi) combine their animal health divisions in an equally owned joint venture named Merial.

      1990s

      • Development of florfenicol, a novel phenicol antibiotic exclusive to animal health (Schering-Plough Animal Health).

      • Introduction of antiparasitic SCALIBOR®, a dog collar to prevent Leishmaniasis from sand fly bites (Intervet).

      1980s

      • Development of first recombinant DNA vaccine (PORCILIS® Porcoli against diarrhea in piglets) by Intervet.

      1970s

      • Introduction of anti-inflammatory drug for horses (Schering-Plough Animal Health).

      • Intervet develops anthelmintic fenbendazole, which is still used today against parasites, such as roundworms and hookworms, that are found in the gastrointestinal and respiratory tracts of chickens.

      • Intervet launches products for reproduction management in farm animals.

      1961

      • Netherlands-based “Koninklijke Zwanenburg Organon” (which later became AKZO NOBEL) acquires Intervet.

      1955

      • Publication of first edition of The MSD Veterinary Manual.

      1950s

      • Schering-Plough Animal Health is established and comes to market with prednisone to treat ketosis in dairy cattle.

      • Intervet develops first fowl pox vaccine for poultry.

      1949

      • Feed manufacturer Wim Hendrix lays the foundation for Intervet in Boxmeer, The Netherlands, where the Animal Health headquarters of todays’ company remained until 2012.

      1940s

      • MSD establishes an Animal Health division and discovers sulfaquinoxaline, the first poultry coccidiostat.

        Photo source: MSD Archives, 2021.
        © 1955 Merck & Co., Inc., Kenilworth, NJ USA. and its affiliates. All rights reserved.

      Our Operations

      We operate in more than 150 countries.

      We’ve achieved our reach through an absolute commitment to regional understanding. It helps us react quickly to changing disease landscapes around the world. We help protect public health and effectively address local concerns.

      Explore our archive of featured stories and learn more about how MSD Animal Health protects the health of animals.